Last updated on July 2019

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL


Brief description of study

B-precursor ALL is an aggressive malignant disease. Therapy is usually stratified according to risk characteristics to ensure that appropriate treatment is administered to patients with high-risk of relapse. In general, pediatric treatment regimens are more intense than those employed in adults and include courses of combination chemotherapy. Standard of care chemotherapy is associated with considerable toxicity. There is a lack of novel treatment options for subjects who relapse or are refractory to treatment. Therefore, innovative therapeutic approaches are urgently needed. Blinatumomab is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T cell activation and a cytotoxic T cell response against CD19 expressing cells. This study will evaluate the event-free survival (EFS) after treatment with blinatumomab when compared to standard of care (SOC) chemotherapy. The effect of blinatumomab on overall survival and reduction of minimal residual disease compared to SOC chemotherapy will also be investigated.

Detailed Study Description

Patients will be randomized in a 1:1 ratio to receive either one cycle of blinatumomab or one block of standard high-risk consolidation chemotherapy. Blinatumomab is administered as a continuous intravenous infusion (CIVI). One cycle of blinatumomab treatment includes 4 weeks of CIVI of blinatumomab. After completing consolidation therapy, the patients should undergo alloHSCT depending on their bone marrow status. The patients will be followed up until the last subject on study is 36 months following alloHSCT or has died, whichever is first.

Clinical Study Identifier: NCT02393859

Find a site near you

Start Over

Research Site

Randwick, Australia
  Connect »

Research Site

Westmead, Australia
  Connect »

Research Site

South Brisbane, Australia
  Connect »

Research Site

Parkville, Australia
  Connect »

Research Site

Innsbruck, Austria
  Connect »

Research Site

Brussels, Belgium
  Connect »

Research Site

Praha 5, Czechia
  Connect »

Research Site

Kobenhavn O, Denmark
  Connect »

Research Site

Bordeaux Cedex, France
  Connect »

Research Site

Marseille cedex 5, France
  Connect »

Research Site

Montpellier cedex 05, France
  Connect »

Research Site

Nantes cedex 1, France
  Connect »

Research Site

Strasbourg Cedex, France
  Connect »

Research Site

Vandoeuvre les Nancy, France
  Connect »

Research Site

Duesseldorf, Germany
  Connect »

Research Site

Erlangen, Germany
  Connect »

Research Site

Frankfurt am Main, Germany
  Connect »

Research Site

Freiburg, Germany
  Connect »

Research Site

Giessen, Germany
  Connect »

Research Site

Hamburg, Germany
  Connect »

Research Site

Hannover, Germany
  Connect »

Research Site

München, Germany
  Connect »

Research Site

Münster, Germany
  Connect »

Research Site

Tübingen, Germany
  Connect »

Research Site

Würzburg, Germany
  Connect »

Research Site

Jerusalem, Israel
  Connect »

Research Site

Petah Tikva, Israel
  Connect »

Research Site

Tel Aviv, Israel
  Connect »

Research Site

Tel Hashomer, Israel
  Connect »

Research Site

Monza (MB), Italy
  Connect »

Research Site

Rotterdam, Netherlands
  Connect »

Research Site

Utrecht, Netherlands
  Connect »

Research Site

Bydgoszcz, Poland
  Connect »

Research Site

Lisboa, Portugal
  Connect »

Research Site

Moscow, Russian Federation
  Connect »

Research Site

Saint Petersburg, Russian Federation
  Connect »

Research Site

Santander, Spain
  Connect »

Research Site

Barcelona, Spain
  Connect »

Research Site

Santiago de Compostela, Spain
  Connect »

Research Site

Boadilla del Monte, Spain
  Connect »

Research Site

El Palmar, Spain
  Connect »

Research Site

Stockholm, Sweden
  Connect »

Research Site

Basel, Switzerland
  Connect »

Research Site

Zuerich, Switzerland
  Connect »

Research Site

Birmingham, United Kingdom
  Connect »

Research Site

Bristol, United Kingdom
  Connect »

Research Site

Glasgow, United Kingdom
  Connect »

Research Site

London, United Kingdom
  Connect »

Research Site

Manchester, United Kingdom
  Connect »

Research Site

Newcastle upon Tyne, United Kingdom
  Connect »

Research Site

Sheffield, United Kingdom
  Connect »

Research Site

Sutton, United Kingdom
  Connect »

Research Site

München, Germany
  Connect »

Research Site

Münster, Germany
  Connect »

Research Site

Tübingen, Germany
  Connect »

Research Site

Würzburg, Germany
  Connect »

Research Site

München, Germany
  Connect »

Research Site

Münster, Germany
  Connect »

Research Site

Tübingen, Germany
  Connect »

Research Site

Würzburg, Germany
  Connect »

Research Site

München, Germany
  Connect »

Research Site

Münster, Germany
  Connect »

Research Site

Tübingen, Germany
  Connect »

Research Site

Würzburg, Germany
  Connect »

Research Site

Sao Paulo, Brazil
  Connect »

Research Site

München, Germany
  Connect »

Research Site

Münster, Germany
  Connect »

Research Site

Tübingen, Germany
  Connect »

Research Site

Würzburg, Germany
  Connect »

Research Site

Monterrey, Mexico
  Connect »

Research Site

München, Germany
  Connect »

Research Site

Münster, Germany
  Connect »

Research Site

Tübingen, Germany
  Connect »

Research Site

Würzburg, Germany
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.